Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2021
Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung CancerMichael Skwarski, Daniel R McGowan, Elizabeth Belcher, et al.
Journal of Medicinal Chemistry|December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological MalignanciesBernard Barlaam, Robert Casella, Justin Cidado, et al.
BMJ Open|June 11, 2018
Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocolSybil A McAuley, Martin I de Bock, Vijaya Sundararajan, et al.
Lancet (London, England)|December 17, 2019
Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trialChristopher C Butler, Alike W van der Velden, Emily Bongard, et al.
Nature Medicine|December 1, 2025
Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trialPaul Edison, Grazia Daniela Femminella, Craig Ritchie, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
BMJ Open|August 7, 2023
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe diseaseOghenekome Gbinigie, Emma Ogburn, Julie Allen, et al.
Diabetes Care|December 7, 2021
Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes: Uptake and Outcomes Over 2 Years, a Population-Based StudyStephanie R Johnson, Deborah J Holmes-Walker, Melissa Chee, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Pageof 9